人自然突变的雄激素受体结构与功能的研究

基本信息
批准号:39970161
项目类别:面上项目
资助金额:13.00
负责人:卢建
学科分类:
依托单位:中国人民解放军第二军医大学
批准年份:1999
结题年份:2002
起止时间:2000-01-01 - 2002-12-31
项目状态: 已结题
项目参与者:于小玲,王晓慧,李忆东,张金山,夏冰,王钢,谢靖
关键词:
自然突变转录激活雄激素受体
结项摘要

Androgens play important roles mediated by androgen receptor (AR) in male sexual differentiation and prostate growth in the adult. Genetic alterations in AR gene may result in androgen insensitivity syndromes (AIS), and are also believed to involved in formation and progression of prostate cancer (PC). We have identified Seven kinds of novel mutations in AR from patients with AIS (T2919 deletion、G2882deletion) or advanced PC (G142V, D221H, S296R, E872Q, and M886I) by PCR-SSCP analysis. In this study, we constructed mutant AR cDNA expression plasmids by site directed mutagenesis and investigated how mutations of AR affect their functions as well as their pathological significance. .Androgen specific binding capacity of the wilde type and mutant AR were determined by whole cell ligand-binding assay in transient expression of wilde typ and mutant AR in COS-7 cell. The androgen binding capacity were lost completely in AR mutants (T2919 deletion、G2882 deletion) with a single base deletion that caused frameshift. Furthermore, the transcriptional activities of these two mutants were also lost completely by assaying in CV-1 cells cotranfected with an androgen responsive Luciferase reporter vector (MMTV-Luc). These functional alterations are consistent with the completely AIS phenotype in affected males. .Equilibrium dissociation constants (Kd) and maximal specific binding capacity (Bmax) of the AR missense mutants (G142V, D221H, S296R,E872Q, and M886I) found in PC were no obviously alterations compared with wild type AR. However, they showed increased transactivational activitiy responsion to different ligands. for example, G142V and D221H variants induced 79% and 69% more transcriptional activities, respectively in the presence of DHT at 2′10-9mol/L than wild type AR (P<0.01). Induced transcriptional activities by E872Q variant in response to 1mmol/L estradiol, progesterone, and the androgen antagonist CPA were about two-fold as wild type AR (P<0.01), indicating that there is alteration of the ligand specificity in E872Q variant. Moreover, in the presence of the AR coactivators TIF-2 or CBP, E872Q and M886I variants showed abnormally increased transcriptional activity in response to DHT (p<0.01). Increased trascription activity of these mutant AR in different conditions may associate with progression of PC and failure of AR-targeted therapies..In this studies we demonstrated that AR mutations we have identified may alterate or lose their functions and provided insight into the molecular mechanisms involved in the role of AR gene mutation in the formation, development and progression of diseases (AIS and prostate cancer)..

以从国人雄激素抵抗征患者和前列腺癌(PC)组织中发现的种新的雄激素受体(AR)突变型为模型,研究突变AR的结合特征,它们与靶基因中雄激素反应元件的结合及转录活性,确定突变AR对其介导的信号转导通路和转录激活作用的影响环节,以进一步阐明AR结构与功能的关系,受体对靶基因的转录调节机制,并探讨突变AR的病理意义及与临床PC治疗的关系。

项目摘要

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

DeoR家族转录因子PsrB调控黏质沙雷氏菌合成灵菌红素

DeoR家族转录因子PsrB调控黏质沙雷氏菌合成灵菌红素

DOI:10.3969/j.issn.1673-1689.2021.10.004
发表时间:2021
2

自然灾难地居民风险知觉与旅游支持度的关系研究——以汶川大地震重灾区北川和都江堰为例

自然灾难地居民风险知觉与旅游支持度的关系研究——以汶川大地震重灾区北川和都江堰为例

DOI:10.12054/lydk.bisu.148
发表时间:2020
3

转录组与代谢联合解析红花槭叶片中青素苷变化机制

转录组与代谢联合解析红花槭叶片中青素苷变化机制

DOI:
发表时间:
4

地震作用下岩羊村滑坡稳定性与失稳机制研究

地震作用下岩羊村滑坡稳定性与失稳机制研究

DOI:10.16285/j.rsm.2019.1374
发表时间:2020
5

木薯ETR1基因克隆及表达分析

木薯ETR1基因克隆及表达分析

DOI:10.3969/j.issn.2095-1191.2020.01.003
发表时间:2020

卢建的其他基金

批准号:81472690
批准年份:2014
资助金额:72.00
项目类别:面上项目
批准号:39970311
批准年份:1999
资助金额:11.00
项目类别:面上项目
批准号:30971157
批准年份:2009
资助金额:31.00
项目类别:面上项目
批准号:30470671
批准年份:2004
资助金额:20.00
项目类别:面上项目
批准号:91029722
批准年份:2010
资助金额:50.00
项目类别:重大研究计划
批准号:39670300
批准年份:1996
资助金额:8.50
项目类别:面上项目
批准号:39270310
批准年份:1992
资助金额:4.00
项目类别:面上项目

相似国自然基金

1

雄激素抵抗症与雄激素受体

批准号:39270310
批准年份:1992
负责人:卢建
学科分类:H0702
资助金额:4.00
项目类别:面上项目
2

前列腺癌雄激素受体表达、突变研究以及以雄激素受体为靶基因的基因治疗探索

批准号:30772168
批准年份:2007
负责人:郭应禄
学科分类:H1819
资助金额:28.00
项目类别:面上项目
3

基于突变型雄激素受体结构的新型拮抗剂设计及构效关系研究

批准号:21372260
批准年份:2013
负责人:李志裕
学科分类:B0706
资助金额:80.00
项目类别:面上项目
4

人B淋巴细胞生长因子受体的结构与功能

批准号:39080030
批准年份:1990
负责人:朱立平
学科分类:H1101
资助金额:4.50
项目类别:专项基金项目